FDA Approves Self-Administered Migraine Treatment
(Reuters) -The U.S. Food and Drug Administration has approved Amneal Pharmaceuticals' self-administered migraine drug, giving way to a quick and more convenient treatment option for patients.
The treatment, branded as Brekiya, delivers a single dose of the drug called dihydroergotamine mesylate via an autoinjector. It is approved for the treatment of acute cases of migraine and severe, one-sided pain in the head called cluster headaches in adults, the drugmaker said on Thursday.
Migraine, characterized by recurrent attacks of throbbing pain on one side of the head, causes symptoms such as nausea, vomiting and sensitivity to light.
The treatment offers a beneficial alternative to those who respond poorly to oral therapies, Amneal said.
Oral migraine treatments include Axsome Therapeutics' recently approved Symbravo and Pfizer's Nurtec ODT.
Pfizer also sells a nasal spray, Zavzpret, for the treatment of acute migraine.
Amneal's single-dose drug can be administered by patients into the middle of the thigh and does not require refrigeration or assembly of the device.
Brekiya will be available in the U.S. by the second half of the year and Amneal will disclose price details close to the launch, it said.
The FDA had previously declined to approve the application citing issues at a third-party manufacturing site. The company said last year it had transferred production to an in-house facility.
(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Devika Syamnath)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Former LeBron James Teammate Tells Wild Club Story About Lakers Star
Former LeBron James Teammate Tells Wild Club Story About Lakers Star originally appeared on Athlon Sports. Los Angeles Lakers star LeBron James takes precise care of his body, which has helped him play 22 seasons in the NBA at an elite level. Advertisement James is 40 years old. He's the oldest active player in the NBA. The average person wouldn't know that by watching him play, as James made the All-NBA Second Team this year and became the oldest player in NBA history to receive an MVP vote, breaking Michael Jordan's 23-year-old record. A four-time MVP, James has played for the Cleveland Cavaliers (twice), Miami Heat and Lakers. He's a four-time champion and a four-time Finals MVP. James is the only player in NBA history to win a Finals MVP Award with three teams. Los Angeles Lakers star LeBron James© Soobum Im-Imagn Images A future Hall of Famer, James won his first two titles with the Heat in 2012 and 2013. Mario Chalmers, who was on those Miami teams, recently told NFL legend Shannon Sharpe that James used to get treatment in the clubs. Advertisement "I tell people this all the time, Bron will really get treatment if he was in the club. Like, he would literally have something on his knees or something on his back inside the club. So it's like why is somebody doing that, like that's a real dedication to just be in the club with treatment." Chalmers said. Sharpe went on asking what were the kind of treatments he is doing in the club. "Not ice bags, it'd be like the stim, like the stim machine that shoot electrolyte or electricity in your knees and stuff like that. He always have something [for] recovery." James has said many times that he takes recovery very seriously. The leading scorer in NBA history has never undergone surgery on his body because of an injury. The small forward is arguably the most durable athlete in NBA history. Advertisement Arguably the greatest player of all time, James has career averages of 27.0 points, 7.5 rebounds, 7.4 assists, 1.5 steals and 0.7 blocks. He's the only player in NBA history to rank top five all-time in points and assists. James, who turns 41 in December, has a player option to return to the Lakers next season worth $52.6 million. The King is widely expected to pick up his option and play his 23rd NBA season. Related: Shai Gilgeous-Alexander Predicted to Repeat Feat Not Seen Since LeBron James This story was originally reported by Athlon Sports on Jun 1, 2025, where it first appeared.
Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Medscape
an hour ago
- Medscape
ED Work Environment Discord Affects Patient Outcomes
In a recent study, emergency nurses and physicians in approximately half of the study hospitals disagreed on the quality of the work environment. An environment rated "unfavorable" by both groups was significantly associated with worse clinician and patient outcomes. METHODOLOGY: A cross-sectional analysis included emergency department (ED) clinicians (1190 nurses and 414 physicians) from 47 Magnet hospitals who completed the 2021 US Clinician Wellbeing Study. Researchers classified hospitals into profiles according to the level of agreement between nurses and physicians regarding the hospital work environment. Researchers assessed clinician job outcomes (burnout, job dissatisfaction, and intent to leave), patient safety, and quality-of-care metrics. TAKEAWAY: Hospital profiles revealed three distinct patterns: "Agree, Unfavorable Environment" (10 hospitals); "Agree, Favorable Environment" (15 hospitals); and "Disagree, Less Favorable Environment Among Nurses" (22 hospitals). Compared with hospitals where clinicians agreed on a favorable environment, hospitals where clinicians agreed on an unfavorable environment had significantly higher rates of burnout (β, 25.8), job dissatisfaction (β, 32.5), intent to leave (β, 31.7), and unfavorable patient safety grades (β, 29.1), after adjustment for hospital characteristics ( P < .001 for all). < .001 for all). Hospitals where nurses rated the environment less favorably than physicians demonstrated increased burnout (β, 15.4; P < .001) and poorer patient safety grades (β, 11.9; P < .01), after adjustment for hospital characteristics. < .001) and poorer patient safety grades (β, 11.9; < .01), after adjustment for hospital characteristics. Compared with physicians in hospitals with an "Agree, Favorable" profile, those in hospitals rated as having an "Unfavorable" work environment showed significantly higher rates for all outcomes except burnout and patient-care quality. Similarly, nurses in hospitals with a "Disagree, Less Favorable Among Nurses" profile experienced higher rates across all job-related and patient-care outcomes. IN PRACTICE: "This cross-sectional study found that ED nurses and physicians in close to half of study hospitals disagreed on the quality of their work environment. Clinician job and patient outcomes were worse when both clinicians rated their work environment unfavorably and when nurses only reported their work environments as unfavorable," the authors wrote. "The implication of these findings is that, if two essential partners in emergency care within the same institution do not agree on the deficiencies in ED work environments, significant interdisciplinary research is needed to bridge these gaps and disparate experiences," they added. SOURCE: The study was led by Jane Muir, Center for Health Outcomes and Policy Research, School of Nursing, University of Pennsylvania, Philadelphia. It was published online on May 16, 2025, in BMC Health Services Research . LIMITATIONS: The study included only Magnet hospitals, which are known for favorable work environments and good physician-nurse collaboration, suggesting the findings may have underestimated the variation in clinician work environment agreement across all hospitals. The cross-sectional design prevented causal inference, and the sample had more nurses than physicians. DISCLOSURES: The research was funded by the Clinician Well-being Study Consortium and the National Institutes of Health. Additionally, it was supported by the Agency for Healthcare Research and Quality, the National Institute of Nursing Research, the National Clinician Scholars Program, and the Emergency Medicine Foundation/Emergency Nurses Association Foundation. The authors reported having no relevant conflicts of interest.
